The importance of drug scheduling and recovery phases in determining drug activity - improving etoposide efficacy in BCR-ABL-positive CML cells

Author： Liu W.M.   Lawrence A.J.   Joel S.P.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.38, Iss.6, 2002-01, pp. : 842-850

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells

By          

International Journal of Oncology, Vol. 42, Iss. 2, 2013-01 ,pp. : 419-428

Spandidos Publications

Access to resources Recommend Favorite

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate

By Hardling Mats   Wei Yuan   Palmqvist Lars   Swolin Birgitta   Stockelberg Dick   Gustavsson Bengt   Ekeland-Sjöberg Kerstin   Wadenvik Hans   Ricksten Anne  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 349-358

Humana Press, Inc

Access to resources Recommend Favorite

Unexpected properties of endostatin-producing mouse BCR-ABL-transformed cells

By          

International Journal of Oncology, Vol. 40, Iss. 2, 2012-01 ,pp. : 487-493

Spandidos Publications

Access to resources Recommend Favorite

Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control

By  

Current Cancer Therapy Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 303-309

Bentham Science Publishers

Access to resources Recommend Favorite

Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells

By              

Oncology Reports, Vol. 27, Iss. 1, 2012-01 ,pp. : 232-237

Spandidos Publications

Access to resources Recommend Favorite